Aditxt, Inc. Research and Development Expense
Aditxt, Inc. (ADTX) reported Research and Development Expense of $1.05 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-20
- Aditxt, Inc. research and development expense for the quarter ending 2026-03-31 was $1.05M, a 13.41% decline year-over-year.
- Aditxt, Inc. research and development expense for the quarter ending 2025-12-31 was $548.56K, a 21.18% decline year-over-year.
- Aditxt, Inc. research and development expense for the quarter ending 2025-09-30 was $672.04K, a 36.72% increase year-over-year.
- Aditxt, Inc. research and development expense for the quarter ending 2025-06-30 was $764.33K, a 50.80% decline year-over-year.
- Aditxt, Inc. research and development expense for fiscal 2025 was $3.19M, a 70.66% decline from fiscal 2024.
- Aditxt, Inc. research and development expense for fiscal 2024 was $10.89M, a 53.88% increase from fiscal 2023.
- Aditxt, Inc. research and development expense for fiscal 2023 was $7.07M, a 2.67% decline from fiscal 2022.
- Aditxt, Inc. research and development expense for fiscal 2022 was $7.27M, a 44.13% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.05M 10-Q · filed 2026-05-20 | $1.60M derived: sum of 2 quarters · filed 2026-05-20 | $2.27M derived: sum of 3 quarters · filed 2026-05-20 | $3.03M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $548.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.22M derived: sum of 2 quarters · filed 2026-03-31 | $1.98M derived: sum of 3 quarters · filed 2026-03-31 | $3.19M 10-K · filed 2026-03-31 |
| 2025-09-30 | $672.04K 10-Q · filed 2025-11-18 | $1.44M derived: sum of 2 quarters · filed 2025-11-18 | $2.65M 10-Q · filed 2025-11-18 | $3.34M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $764.33K 10-Q · filed 2025-08-14 | $1.97M 10-Q · filed 2025-08-14 | $2.67M derived: sum of 3 quarters · filed 2026-05-20 | $3.16M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $1.21M 10-Q · filed 2026-05-20 | $1.91M derived: sum of 2 quarters · filed 2026-05-20 | $2.40M derived: sum of 3 quarters · filed 2026-05-20 | $3.95M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $695.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.19M derived: sum of 2 quarters · filed 2026-03-31 | $2.74M derived: sum of 3 quarters · filed 2026-03-31 | $10.89M 10-K · filed 2026-03-31 |
| 2024-09-30 | $491.55K 10-Q · filed 2025-11-18 | $2.04M derived: sum of 2 quarters · filed 2025-11-18 | $10.19M 10-Q · filed 2025-11-18 | $14.49M derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $1.55M 10-Q · filed 2025-08-14 | $9.70M 10-Q · filed 2025-08-14 | $14.00M derived: sum of 3 quarters · filed 2025-08-14 | $14.90M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $8.15M 10-Q · filed 2025-05-15 | $12.45M derived: sum of 2 quarters · filed 2025-05-15 | $13.35M derived: sum of 3 quarters · filed 2025-05-15 | $13.83M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.20M derived: sum of 2 quarters · filed 2025-03-31 | $5.69M derived: sum of 3 quarters · filed 2025-03-31 | $7.07M 10-K · filed 2025-03-31 |
| 2023-09-30 | $898.72K 10-Q · filed 2024-11-18 | $1.38M derived: sum of 2 quarters · filed 2024-11-18 | $2.77M 10-Q · filed 2024-11-18 | $5.85M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $484.83K 10-Q · filed 2024-08-19 | $1.87M 10-Q · filed 2024-08-19 | $4.95M derived: sum of 3 quarters · filed 2024-08-19 | $6.52M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $1.39M 10-Q · filed 2024-05-20 | $4.47M derived: sum of 2 quarters · filed 2024-05-20 | $6.04M derived: sum of 3 quarters · filed 2024-05-20 | $7.23M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $4.65M derived: sum of 2 quarters · filed 2024-04-16 | $5.84M derived: sum of 3 quarters · filed 2024-04-16 | $7.27M 10-K · filed 2024-04-16 |
| 2022-09-30 | $1.57M 10-Q · filed 2023-11-14 | $2.76M derived: sum of 2 quarters · filed 2023-11-14 | $4.19M 10-Q · filed 2023-11-14 | $5.89M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.19M 10-Q · filed 2023-08-14 | $2.62M 10-Q · filed 2023-08-14 | $4.32M derived: sum of 3 quarters · filed 2023-08-14 | $5.79M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.43M 10-Q · filed 2023-05-15 | $3.13M derived: sum of 2 quarters · filed 2023-05-15 | $4.60M derived: sum of 3 quarters · filed 2023-05-15 | $5.54M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $3.17M derived: sum of 2 quarters · filed 2023-04-17 | $4.11M derived: sum of 3 quarters · filed 2023-04-17 | $5.04M 10-K · filed 2023-04-17 |
| 2021-09-30 | $1.47M 10-Q · filed 2022-11-14 | $2.40M derived: sum of 2 quarters · filed 2022-11-14 | $3.34M 10-Q · filed 2022-11-14 | $3.76M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $932.75K 10-Q · filed 2022-08-15 | $1.87M 10-Q · filed 2022-08-15 | $2.29M derived: sum of 3 quarters · filed 2022-08-15 | $2.58M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $935.95K 10-Q · filed 2022-05-16 | $1.36M derived: sum of 2 quarters · filed 2022-05-16 | $1.65M derived: sum of 3 quarters · filed 2022-05-16 | $1.67M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $423.49K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $709.30K derived: sum of 2 quarters · filed 2022-03-31 | $737.60K derived: sum of 3 quarters · filed 2022-03-31 | $937.97K 10-K · filed 2022-03-31 |
| 2020-09-30 | $285.81K 10-Q · filed 2021-11-15 | $314.11K derived: sum of 2 quarters · filed 2021-11-15 | $514.48K 10-Q · filed 2021-11-15 | $581.47K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $28.29K 10-Q · filed 2021-08-12 | $228.66K 10-Q · filed 2021-08-12 | $295.66K derived: sum of 3 quarters · filed 2021-08-12 | $315.26K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $200.37K 10-Q · filed 2021-05-12 | $267.36K derived: sum of 2 quarters · filed 2021-05-12 | $286.97K derived: sum of 3 quarters · filed 2021-05-12 | $330.94K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $66.99K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $86.59K derived: sum of 2 quarters · filed 2021-03-25 | $130.57K derived: sum of 3 quarters · filed 2021-03-25 | $175.44K 10-K · filed 2021-03-25 |
| 2019-09-30 | $19.60K 10-Q · filed 2020-11-13 | $63.58K derived: sum of 2 quarters · filed 2020-11-13 | $108.45K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $43.98K 10-Q · filed 2020-08-13 | $88.85K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |